	Patient	Gender	Age [yrs]	Height <sup>a)</sup> [cm]	Weight <sup>a)</sup> [kg]	Melanoma Stage <sup>a)</sup>
	1001	male	82	170	72.0	III
Group I: IFA	1002	male	44	169	64.6	IV
oup.	1003	female	62	158	72.0	III
Ğ	1004	female	29	185	68.0	III
	1005	male	72	185	65.0	III
	1006	male	46	180	75.0	III
ii	1007	female	47	157	79.0	III
Group II: IFA	1008	male	64	170	79.0	III
rou	1009	male	58	181	86.0	III
G	1010	male	26	172	61.2	IV
	1011	male	53	171	75.0	III
g ::	2001	male	61	175	104.0	III
II 0	2002	male	61	175	92.8	III
dn	2003	male	56	174	89.2	III
Group III: Imiquimod	2004	female	69	163	58.2	III
	2005	female	56	168	55.0	III
י: ד	2006	female	61	164	77.7	III
Group IV: intranodal	2007	female	44	164	77.4	III
ano	2008	male	55	186	103.1	III
3r0 ntr	2009	female	63	161	73.2	III
<b></b>	2010	male	57	174	80.1	III

## Supporting Information Table 1. Baseline Characteristics of Patients

<sup>a)</sup> Assesed at screening.


Mean ( $\pm$  SD) patient age for patient groups I, II, III and IV was  $58 \pm 19$ ,  $49 \pm 12$ ,  $61 \pm 5$  and  $56 \pm 7$  years, respectively.

## Supporting Information Table 2. Overview of Results


		Melan-A specific	Anti-Melan-A antibodies		Anti-Qb antibodies		Melan-A expression		HLA class I expression			
		T cells										
		[%]	[ELISA titer]		[ELISA titer]		[%]		[%]		Disease	Lymphadenopathy <sup>b)</sup>
	Patient	Before Highest level after start of	Visit 1	Visit 12	Visit 1	Visit 12	Before vaccination	After vaccination	Before vaccination	After vaccination	status at	
		vaccination vaccination					vaccination	vacchianon	, accontant on	vaccination	study end	
Group I: IFA	1001	0.17 0.46 <sup>a)</sup>	281	26'470	< 1'000	1'050'000	-	-	-	-	-	
	1002	$0.01  0.25^{a}$	21	-	< 1'000	-	80	80	10	10	PD	
	1003	$0.06  0.18^{a}$	10	10'627	< 1'000	697'845	90	90	90	40	PD	
	1004	0.18 0.36 <sup>a)</sup>	57	43'977	< 1'000	1'370'000	-	-	-	-	-	
	1005	0.01 0.04 <sup>a)</sup>	14	5'742	< 1'000	174'107	-	-	-	-	-	
Group II: A +Imiquimod	1006	0.03 0.16 <sup>a)</sup>	25	16'511	< 1'000	452'528	100	70	40	30	-	
	1007	0.09 0.23 <sup>a)</sup>	96	44'780	< 1'000	1'630'000	60	10	30	0	-	
	1008	0.01 0.10 <sup>a)</sup>	20	5'486	< 1'000	533'984	-	-	-	-	-	
	1009	0.05 0.37 <sup>a)</sup>	52	-	< 1'000	-	-	-	-	-	PD	
	1010	$0.08  0.18^{a}$	225	23'531	< 1'000	610'473	-	-	-	-	PD	
IF	1011	0.03 0.19 <sup>a)</sup>	28	8'245	< 1'000	476'915	-	-	-	-	-	
III: nod	2001	0.04 0.05	9	2'273	< 1'000	228'223	80	10	80	30	PD	
	2002	0.06 0.07	-	1'097	-	14'852	-	-	-	-	SD	
Group III: Imiquimod	2003	0.04 0.05	8	-	< 1'000	-	90	90	50	30	PD	
Gro	2004	0.04 0.11 <sup>a)</sup>	116	9'587	< 1'000	204'271	90	40	80	80	SD	
	2005	0.03 0.18 <sup>a)</sup>	30	-	< 1'000	-	-	-	-	-	PD	
Group IV: intranodal	2006	0.08 0.16 <sup>a)</sup>	36	736	< 1'000	23'520	-	-	-	-	SD	
	2007	0.04 0.05	26	278	< 1'000	5'817	-	-	-	-	PD	
	2008	0.03 0.24 <sup>a)</sup>	-	6'216	-	35'725	-	-	-	-	SD	
	2009	0.11 0.25 <sup>a)</sup>	12	1'827	< 1'000	34'598	-	-	-	-	SD	
	2010	0.04 0.06	19	2'733	< 1'000	135'929	90	0	50	40	PD	

<sup>a)</sup> Considered as an immune responder. Linear regression analysis of all 21 patients showed that their age did not correlate with their frequencies of Melan-A specific T cells (R square = 0.002605, P = 0.83). <sup>b)</sup> Defined as clinically palpable and/or radiologically enlarged


PD: Progressive disease; SD: Stable disease



**Trial Design.** Four groups of patients received vaccinations as indicated on the right side of the figure. For each patient, the total trial duration was approximately 9 months. The screening period took up to 4 weeks. The treatment phase, including the seven injections with MelQbG10, lasted 18 weeks and the follow-up phase ended after 36 weeks. All s.c. and i.d. injections were performed in the upper arm left or right alternatively. Injections with IFA were prepared by mixing equal volumes of MelQbG10 with IFA until the two liquids formed a homogenous emulsion. The intranodal injections were performed always in the same inguinal lymph node region. The lymph node dissected region was omitted for vaccine injections. No immunosuppressive medication was used during the study.



Anti-Melan-A and anti-Qb IgG Antibody responses. Geometric mean titers are expressed as reciprocal serum dilutions giving half-optical density in ELISA. Before vaccination (Visit 1) and at study end (Visit 12) anti-Melan A ( $\diamond$ ) and anti-Qb ( $\diamond$ ) titers were measured in patients' blood serum samples. Panel A shows the titers of group I (1mg MelQbG10 + IFA s.c.), Panel B of group II (1mg MelQbG10 + IFA s.c.), Panel B of group II (1mg MelQbG10 + IFA s.c.), and Panel D of group IV (14/42/140mg MelQbG10 i.n.). Mann-Whitney pair wise comparisons were performed. The contrasts of Group I and II vs. Group III and IV were statistically significant for anti-Melan-A and anti-Qb titers (p=0.003 and p=0.001, respectively).



**Frequency and memory- / effector-phenotypes of Melan-A specific T cells.** Results before vaccination (Prevacc) and of a single time point after vaccination with MelQbG10 (six vaccinations), from the same experiments as those for Figures 2 and 3, shown in a similar fashion. Statistical significances have been determined by the Mann-Whitney test. Where significant, P-values are symbolized with \*\* or \* for <0.01 or 0.01-0.049, respectively.